Literature DB >> 33288545

SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment.

Patrick O'Connell1, Sean Hyslop1, Maja K Blake1, Sarah Godbehere1, Andrea Amalfitano1,2, Yasser A Aldhamen3.   

Abstract

T cell exhaustion represents one of the most pervasive strategies tumors employ to circumvent the immune system. Although repetitive, cognate TCR signaling is recognized as the primary driving force behind this phenomenon, and it remains unknown what other forces drive T cell exhaustion in the tumor microenvironment (TME). In this study, we show that activation of the self-ligand SLAMF7 immune receptor on T cells induced STAT1 and STAT3 phosphorylation, expression of multiple inhibitory receptors, and transcription factors associated with T cell exhaustion. Analysis of The Cancer Genome Atlas revealed that SLAMF7 transcript levels were strongly correlated with various inhibitory receptors and that high SLAMF7 expression was indicative of poor survival in clear cell renal cell carcinoma (ccRCC). Targeted reanalysis of a CyTOF dataset, which profiled the TME in 73 ccRCC patients, revealed cell-type-specific SLAMF7 expression patterns, strong correlations between exhausted T cells and SLAMF7+ tumor-associated macrophages (TAMs), and a unique subset of SLAMF7highCD38high TAMs. These SLAMF7highCD38high TAMs showed the strongest correlations with exhausted T cells and were an independent prognostic factor in ccRCC. Confirmatory ex vivo coculture studies validated that SLAMF7-SLAMF7 interactions between murine TAMs and CD8+ T cells induce expression of multiple inhibitory receptors. Finally, mice lacking SLAMF7 show restricted growth of B16-F10 tumors, and CD8+ T cells from these mice express less PD-1 and TOX and exhibited an impaired ability to progress through the exhaustion developmental trajectory to terminal exhaustion. These findings suggest that SLAMF7 might play an important role in modulating T cell function in the TME.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33288545      PMCID: PMC7855551          DOI: 10.4049/jimmunol.2000300

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

1.  Multiparameter analysis of intracellular phosphoepitopes in immunophenotyped cell populations by flow cytometry.

Authors:  Omar D Perez; Dennis Mitchell; Roberto Campos; Guo-Jian Gao; Li Li; Garry P Nolan
Journal:  Curr Protoc Cytom       Date:  2005-05

2.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

3.  YY1 and a unique DNA repeat element regulates the transcription of mouse CS1 (CD319, SLAMF7) gene.

Authors:  Prachi Dongre; Stephen Mathew; Irina Akopova; Ignacy Gryczynski; Porunelloor Mathew
Journal:  Mol Immunol       Date:  2013-01-11       Impact factor: 4.407

Review 4.  Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.

Authors:  Lawrence P Andrews; Hiroshi Yano; Dario A A Vignali
Journal:  Nat Immunol       Date:  2019-10-14       Impact factor: 25.606

5.  SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer.

Authors:  Burcu Yigit; Ninghai Wang; Elisa Ten Hacken; Shih-Shih Chen; Atul K Bhan; Abel Suarez-Fueyo; Eri Katsuyama; George C Tsokos; Nicholas Chiorazzi; Catherine J Wu; Jan A Burger; Roland W Herzog; Pablo Engel; Cox Terhorst
Journal:  Cancer Immunol Res       Date:  2019-07-17       Impact factor: 12.020

6.  Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Authors:  Yasin Şenbabaoğlu; Ron S Gejman; Andrew G Winer; Ming Liu; Eliezer M Van Allen; Guillermo de Velasco; Diana Miao; Irina Ostrovnaya; Esther Drill; Augustin Luna; Nils Weinhold; William Lee; Brandon J Manley; Danny N Khalil; Samuel D Kaffenberger; Yingbei Chen; Ludmila Danilova; Martin H Voss; Jonathan A Coleman; Paul Russo; Victor E Reuter; Timothy A Chan; Emily H Cheng; David A Scheinberg; Ming O Li; Toni K Choueiri; James J Hsieh; Chris Sander; A Ari Hakimi
Journal:  Genome Biol       Date:  2016-11-17       Impact factor: 13.583

7.  TOX is a critical regulator of tumour-specific T cell differentiation.

Authors:  Andrew C Scott; Friederike Dündar; Paul Zumbo; Smita S Chandran; Christopher A Klebanoff; Mojdeh Shakiba; Prerak Trivedi; Laura Menocal; Heather Appleby; Steven Camara; Dmitriy Zamarin; Tyler Walther; Alexandra Snyder; Matthew R Femia; Elizabeth A Comen; Hannah Y Wen; Matthew D Hellmann; Niroshana Anandasabapathy; Yong Liu; Nasser K Altorki; Peter Lauer; Olivier Levy; Michael S Glickman; Jonathan Kaye; Doron Betel; Mary Philip; Andrea Schietinger
Journal:  Nature       Date:  2019-06-17       Impact factor: 49.962

8.  Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity.

Authors:  Shan He; Yongnian Liu; Lijun Meng; Hongxing Sun; Ying Wang; Yun Ji; Janaki Purushe; Pan Chen; Changhong Li; Jozef Madzo; Jean-Pierre Issa; Jonathan Soboloff; Ran Reshef; Bethany Moore; Luca Gattinoni; Yi Zhang
Journal:  Nat Commun       Date:  2017-12-14       Impact factor: 14.919

9.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.

Authors:  Alyson Haslam; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2019-05-03

10.  Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data.

Authors:  Theodoros G Soldatos; Antonia Dimitrakopoulou-Strauss; Lionel Larribere; Jessica C Hassel; Christos Sachpekidis
Journal:  Diagnostics (Basel)       Date:  2018-10-31
View more
  11 in total

1.  Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer.

Authors:  Kelly Kersten; Kenneth H Hu; Alexis J Combes; Bushra Samad; Tory Harwin; Arja Ray; Arjun Arkal Rao; En Cai; Kyle Marchuk; Jordan Artichoker; Tristan Courau; Quanming Shi; Julia Belk; Ansuman T Satpathy; Matthew F Krummel
Journal:  Cancer Cell       Date:  2022-05-26       Impact factor: 38.585

2.  Adverse effects following anti-COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes.

Authors:  Ayesa Syenina; Esther S Gan; Justin Z N Toh; Ruklanthi de Alwis; Lowell Z Lin; Christine Y L Tham; Jia Xin Yee; Yan Shan Leong; Huizhen Sam; Charlene Cheong; Yii Ean Teh; Ian L E Wee; Dorothy H L Ng; Kuan Rong Chan; Jean X Y Sim; Shirin Kalimuddin; Eugenia Z Ong; Jenny G Low; Eng Eong Ooi
Journal:  PLoS Biol       Date:  2022-05-31       Impact factor: 9.593

3.  Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.

Authors:  Samuel E J Preston; Audrey Emond; Filippa Pettersson; Daphné Dupéré-Richer; Madelyn Jean Abraham; Alberto Riva; Mena Kinal; Ryan N Rys; Nathalie A Johnson; Koren K Mann; Sonia V Del Rincón; Jonathan D Licht; Wilson H Miller
Journal:  Mol Cancer Ther       Date:  2022-04-01       Impact factor: 6.009

Review 4.  Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response.

Authors:  Yosef Tsegaye Dabi; Henok Andualem; Sisay Teka Degechisa; Solomon Tebeje Gizaw
Journal:  Biologics       Date:  2022-05-09

5.  Adenoviral delivery of an immunomodulatory protein to the tumor microenvironment controls tumor growth.

Authors:  Patrick O'Connell; Maja K Blake; Yuliya Pepelyayeva; Sean Hyslop; Sarah Godbehere; Ariana M Angarita; Cristiane Pereira-Hicks; Andrea Amalfitano; Yasser A Aldhamen
Journal:  Mol Ther Oncolytics       Date:  2021-12-06       Impact factor: 6.311

Review 6.  Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.

Authors:  Shih-Feng Cho; Lijie Xing; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

7.  Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.

Authors:  Libin Zhou; Hualong Fang; Fei Guo; Min Yin; Huimin Long; Guobin Weng
Journal:  J Clin Lab Anal       Date:  2022-07-08       Impact factor: 3.124

8.  Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma.

Authors:  Linping Xu; Meimei Yan; Jianpeng Long; Mengmeng Liu; Hui Yang; Wei Li
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

9.  Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals.

Authors:  Holger Lingel; Stefan Meltendorf; Ulrike Billing; Christoph Thurm; Katrin Vogel; Christiane Majer; Florian Prätsch; Dirk Roggenbuck; Hans-Gert Heuft; Thomas Hachenberg; Eugen Feist; Dirk Reinhold; Monika C Brunner-Weinzierl
Journal:  J Autoimmun       Date:  2021-06-21       Impact factor: 7.094

Review 10.  PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies.

Authors:  Lei Ding; Hui Yu Dong; Tian Ren Zhou; Yu Hao Wang; Tao Yan; Jun Chen Li; Zhong Yuan Wang; Jie Li; Chao Liang
Journal:  Cancer Med       Date:  2021-08-12       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.